These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36102261)

  • 1. Rates of Elective Percutaneous Coronary Intervention in England and Wales: Impact of COURAGE and ORBITA Trials.
    Rashid M; Stevens C; Wijeysundera HC; Curzen N; Khoo CW; Mohamed MO; Aktaa S; Wu J; Ludman PF; Mamas MA
    J Am Heart Assoc; 2022 Sep; 11(18):e025426. PubMed ID: 36102261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent changes in practice of elective percutaneous coronary intervention for stable angina.
    Ahmed B; Dauerman HL; Piper WD; Robb JF; Verlee MP; Ryan TJ; Goldberg D; Boss RA; Phillips WJ; Fedele F; Butzel D; Malenka DJ;
    Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):300-5. PubMed ID: 21505155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).
    Zhang Z; Jones P; Weintraub WS; Mancini GBJ; Sedlis S; Maron DJ; Teo K; Hartigan P; Kostuk W; Berman D; Boden WE; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003971. PubMed ID: 29752388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.
    Borden WB; Redberg RF; Mushlin AI; Dai D; Kaltenbach LA; Spertus JA
    JAMA; 2011 May; 305(18):1882-9. PubMed ID: 21558519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of Life Assessment in Trials of Revascularization for Chronic Stable Angina: Insights from ORBITA and the Implications of Blinding.
    Nowbar AN; Francis DP; Al-Lamee RK
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):1011-1018. PubMed ID: 34417901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease.
    Al-Lamee R; Howard JP; Shun-Shin MJ; Thompson D; Dehbi HM; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik IS; Cook C; Ahmad Y; Sharp ASP; Gerber R; Baker C; Kaprielian R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom SA; Davies JE; Francis DP
    Circulation; 2018 Oct; 138(17):1780-1792. PubMed ID: 29789302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial.
    McCreanor V; Nowbar A; Rajkumar C; Barnett AG; Francis D; Graves N; Boden WE; Weintraub WS; Al-Lamee R; Parsonage WA
    BMJ Open; 2021 Feb; 11(2):e044054. PubMed ID: 33563623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of the BARI 2D and COURAGE trials: the evolving role of percutaneous coronary intervention.
    Holper EM; Addo T
    Coron Artery Dis; 2010 Nov; 21(7):397-401. PubMed ID: 20634692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry.
    Motivala AA; Parikh V; Roe M; Dai D; Abbott JD; Prasad A; Mukherjee D
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1639-48. PubMed ID: 27539683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in PCI volume after negative results from the COURAGE trial.
    Howard DH; Shen YC
    Health Serv Res; 2014 Feb; 49(1):153-70. PubMed ID: 23829189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in geographic variation in the use of percutaneous coronary intervention for stable ischemic heart disease after publication of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
    Mohan AV; Fazel R; Huang PH; Shen YC; Howard D
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):125-30. PubMed ID: 24347661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex high-risk and indicated percutaneous coronary intervention for stable angina: Does operator volume influence patient outcome?
    Kinnaird T; Gallagher S; Spratt JC; Ludman P; de Belder M; Copt S; Anderson R; Walsh S; Hanratty C; Curzen N; Banning A; Mamas M
    Am Heart J; 2020 Apr; 222():15-25. PubMed ID: 32004796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trend in percutaneous coronary intervention volume following the COURAGE and BARI-2D trials: insight from over 8.1 million percutaneous coronary interventions.
    Bangalore S; Gupta N; Généreux P; Guo Y; Pancholy S; Feit F
    Int J Cardiol; 2015 Mar; 183():6-10. PubMed ID: 25662046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immediate impact of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial on the management of stable angina.
    Atwater BD; Oujiri J; Wolff MR
    Clin Cardiol; 2009 Aug; 32(8):E1-3. PubMed ID: 19536842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease.
    Simader FA; Rajkumar CA; Foley MJ; Ahmed-Jushuf F; Chotai S; Bual N; Khokhar A; Gohar A; Lampadakis I; Ganesananthan S; Pathimagaraj RH; Nowbar A; Davies JR; Keeble TR; O'Kane PD; Haworth P; Routledge H; Kotecha T; Spratt JC; Williams R; Nijjer SS; Sen S; Curzen N; Sinha M; Howard JP; Cole G; Harrell FE; Francis DP; Shun-Shin MJ; Al-Lamee RK;
    J Am Coll Cardiol; 2024 Jul; 84(1):13-24. PubMed ID: 38759906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
    Al-Lamee R; Thompson D; Dehbi HM; Sen S; Tang K; Davies J; Keeble T; Mielewczik M; Kaprielian R; Malik IS; Nijjer SS; Petraco R; Cook C; Ahmad Y; Howard J; Baker C; Sharp A; Gerber R; Talwar S; Assomull R; Mayet J; Wensel R; Collier D; Shun-Shin M; Thom SA; Davies JE; Francis DP;
    Lancet; 2018 Jan; 391(10115):31-40. PubMed ID: 29103656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COURAGE, ORBITA, and ISCHEMIA: Percutaneous Coronary Intervention for Stable Coronary Artery Disease.
    Teoh Z; Al-Lamee RK
    Interv Cardiol Clin; 2020 Oct; 9(4):469-482. PubMed ID: 32921371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Percutaneous coronary intervention in stable angina pectoris : Objective randomised blinded investigation with optimal medical therapy of angioplasty in stable angina (ORBITA) trial].
    Kugler C; Wöhrle J; Nitschmann S
    Internist (Berl); 2018 Sep; 59(9):993-996. PubMed ID: 30073442
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of policy alterations on elective percutaneous coronary interventions in Japan.
    Morishita T; Takada D; Shin JH; Kunisawa S; Fushimi K; Imanaka Y
    Heart; 2023 Mar; 109(8):612-618. PubMed ID: 36627183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial.
    Nowbar AN; Rajkumar C; Foley M; Ahmed-Jushuf F; Howard JP; Seligman H; Petraco R; Sen S; Nijjer SS; Shun-Shin MJ; Keeble TR; Sohaib A; Collier D; McVeigh P; Harrell FE; Francis DP; Al-Lamee RK
    EuroIntervention; 2022 Apr; 17(18):1490-1497. PubMed ID: 35156616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.